Department of Obstetrics and Gynecology, St. Luke's University Health Network, Allentown, PA, USA.
Department of Surgery, George Washington University School of Medicine & Health Sciences, Washington, DC, USA.
Sci Rep. 2021 Jul 19;11(1):14709. doi: 10.1038/s41598-021-93413-3.
Obstetric hemorrhage is one of the leading preventable causes of maternal mortality in the United States. Although hemorrhage risk-prediction models exist, there remains a gap in literature describing if these risk-prediction tools can identify composite maternal morbidity. We investigate how well an established obstetric hemorrhage risk-assessment tool predicts composite hemorrhage-associated morbidity. We conducted a retrospective cohort analysis of a multicenter database including women admitted to Labor and Delivery from 2016 to 2018, at centers implementing the Association of Women's Health, Obstetric, and Neonatal Nurses risk assessment tool on admission. A composite morbidity score incorporated factors including obstetric hemorrhage (estimated blood loss ≥ 1000 mL), blood transfusion, or ICU admission. Out of 56,903 women, 14,803 (26%) were categorized as low-risk, 26,163 (46%) as medium-risk and 15,937 (28%) as high-risk for obstetric hemorrhage. Composite morbidity occurred at a rate of 2.2%, 8.0% and 11.9% within these groups, respectively. Medium- and high-risk groups had an increased combined risk of composite morbidity (diagnostic OR 4.58; 4.09-5.13) compared to the low-risk group. This established hemorrhage risk-assessment tool predicts clinically-relevant composite morbidity. Future randomized trials in obstetric hemorrhage can incorporate these tools for screening patients at highest risk for composite morbidity.
产科出血是美国孕产妇死亡的主要可预防原因之一。尽管存在出血风险预测模型,但文献中仍存在空白,描述这些风险预测工具是否可以识别复合产妇发病率。我们研究了一种既定的产科出血风险评估工具在预测复合出血相关发病率方面的表现。我们对 2016 年至 2018 年期间在实施妇女健康、产科和新生儿护士协会风险评估工具的中心接受分娩的多中心数据库进行了回顾性队列分析。复合发病率评分纳入了产科出血(估计失血量≥1000 毫升)、输血或 ICU 入院等因素。在 56903 名女性中,14803 名(26%)被归类为低危,26163 名(46%)为中危,15937 名(28%)为高危。在这些组中,复合发病率的发生率分别为 2.2%、8.0%和 11.9%。中危和高危组的复合发病率综合风险增加(诊断 OR 4.58;4.09-5.13),与低危组相比。这种既定的出血风险评估工具可预测临床相关的复合发病率。未来的产科出血随机试验可以将这些工具纳入用于筛选复合发病率最高的患者。